Treatment of HER2-positive breast cancer: looking backwards briefly
Mené sur 282 patientes atteintes d'un cancer du sein HER2+, cet essai de phase III évalue l'efficacité, du point de vue du pourcentage de patientes avec réponse pathologique complète, et la toxicité de deux modes d'administration (séquentiel ou concomitant) du trastuzumab en combinaison avec une chimiothérapie néoadjuvante
The successes of HER2-directed treatments for breast cancer are almost unparalleled in oncology. These treatments represent the ideal of finding a target that is preferentially overexpressed in tumour and underexpressed in normal tissue, resulting in a substantial response. The introduction of trastuzumab-containing regimens lowered mortality of women with stage IV disease by 20%, and has enabled more than 30% of women with early stage disease to be practically cured...
The Lancet Oncology , commentaire, 2012